Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022037
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the resolution of the fifth interim meeting of the Fifth Board of supervisors in 2022
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) the fifth supervisory committee
The fifth interim meeting of the board of directors in 2022 voted by communication on March 7, 2022
Held in style. The notice of the meeting was notified to all supervisors in writing on March 7, 2022
Yes. The meeting was convened and presided over by Ms. Xiao man, chairman of the board of supervisors of the company. There were 3 supervisors who should attend the meeting and 3 supervisors who actually attended the meeting. The meeting was held in accordance with the relevant provisions of laws, regulations, rules and the articles of association, and the meeting was legal and effective. The meeting considered and adopted the following proposals:
1、 Notice period on Exemption of the fifth interim meeting of the Fifth Board of supervisors in 2022
Limited motion
Due to work needs, upon the proposal of the chairman of the board of supervisors and the deliberation and voting of all supervisors, it is agreed to waive the notice period of the fifth interim meeting of the Fifth Board of supervisors in 2022 and no longer
The meeting was notified three days in advance and decided to convene the fifth session of the board of supervisors on March 7, 2022
The fifth interim meeting of the conference in 2022.
Voting status of the proposal: 3 affirmative votes, 0 negative votes, 0 abstention votes, passed
Yes.
2、 Discussion on the company’s plan for non-public offering of shares in 2022 (Revised Draft)
case
For details of this proposal, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on the date of disclosure of this announcement Company Announcement No. 2022038 published.
Voting status of the proposal: 3 affirmative votes, 0 negative votes, 0 abstention votes, passed
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Yes.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of supervisors
March 7, 2022
